DOI QR코드

DOI QR Code

Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) Genes in Thai Cervical Cancer Patients with HPV 16 Infection

  • Chansaenroj, Jira (Center of Excellence in Clinical Virology, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Theamboonlers, Apiradee (Center of Excellence in Clinical Virology, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Junyangdikul, Pairoj (Department of Pathology, Samitivej Srinakharin Hospital) ;
  • Swangvaree, Sukumarn (Department of Gynecologic Oncology, National Cancer Institute) ;
  • Karalak, Anant (Department of Pathology, National Cancer Institute) ;
  • Chinchai, Teeraporn (Department of Microbiology, Faculty of Medicine, Srinakharinwirot University) ;
  • Poovorawan, Yong (Center of Excellence in Clinical Virology, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University)
  • Published : 2013.01.31

Abstract

The risk of cervical cancer development in women infected with HPV varies in relation to the individual host's genetic makeup. Many studies on polymorphisms as genetic factors have been aimed at analyzing associations with cervical cancer. In this study, single nucleotide polymorphisms (SNPs) in 3 genes were investigated in relation to cervical cancer progression in HPV16 infected women with lesions. Two thousand cervical specimens were typed by PCR sequencing methods for TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566). Ninety two HPV16 positive cases and thirty two normal cases were randomly selected. Analysis of TP53 (rs1042522) showed a significantly higher frequency in cancer samples (OR=1.22, 95%CI=1.004-1.481, p-value=0.016) while differences in frequency were not significant within each group (p-value=0.070). The genotype distributions of p16 (rs11515 and rs3088440) and NQO1 (rs1800566) did not show any significantly higher frequency in cancer samples (p-value=0.106, 0.675 and 0.132, respectively) or within each group (p-value=0.347, 0.939 and 0.111, respectively). The results indicated that the polymorphism in TP53 (rs1042522) might be associated with risk of cervical cancer development in HPV16 infected women. Further studies of possible mechanisms of influence on cervical cancer development would be useful to manage HPV infected patients.

References

  1. Sousa H, Santos AM, Pinto D, Medeiros R (2011). Is there a biological plausibility for p53 codon 72 polymorphism influence on cervical cancer development? Acta Med Port, 24, 127-34.
  2. Sousa H, Santos AM, Pinto D, Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med, 20, 731-41.
  3. Storey A, Thomas M, Kalita A, et al (1998). Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature, 393, 229-34. https://doi.org/10.1038/30400
  4. Thakur N, Hussain S, Nasare V, et al (2012). Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep, 39, 407-14. https://doi.org/10.1007/s11033-011-0752-z
  5. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
  6. Thurow HS, Haack R, Hartwig FP, et al (2011). TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort. J Biosci, 36, 823-31. https://doi.org/10.1007/s12038-011-9147-5
  7. Tsvetkov P, Reuven N, Shaul Y (2010). Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ, 17, 103-8. https://doi.org/10.1038/cdd.2009.67
  8. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  9. Yan L, Na W, Shan K, et al (2008). p16 (CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int J Gynecol Cancer, 18, 30-5. https://doi.org/10.1111/j.1525-1438.2007.00953.x
  10. Brooks CL, Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell, 21, 307-15. https://doi.org/10.1016/j.molcel.2006.01.020
  11. Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, et al (2010). Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev, 11, 117-22.
  12. Chattopadhyay K (2011). A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet, 17, 132-44. https://doi.org/10.4103/0971-6866.92087
  13. Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606. https://doi.org/10.7314/APJCP.2012.13.2.599
  14. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87. https://doi.org/10.1158/1055-9965.EPI-05-0899
  15. Eltahir HA, Elhassan AM, Ibrahim ME (2012). Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mol Med Report, 6, 473-6.
  16. Geddert H, Kiel S, Zotz RB, et al (2005). Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol, 131, 803-8. https://doi.org/10.1007/s00432-005-0021-4
  17. Hemminki K, Dong C, Vaittinen P (1999). Familial risks in cervical cancer: Is there a hereditary component? Int J Cancer, 82, 775-81. https://doi.org/10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V
  18. Hu X, Zhang Z, Ma D, et al (2010). TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev, 19, 755-61. https://doi.org/10.1158/1055-9965.EPI-09-0886
  19. Jee SH, Won SY, Yun JE, et al (2004). Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet, 85, 301-8. https://doi.org/10.1016/j.ijgo.2003.08.017
  20. Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-54. https://doi.org/10.1038/bjc.1997.474
  21. Kohaar I, Thakur N, Salhan S, et al (2007). TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol, 29, 249-56.
  22. Koushik A, Platt RW, Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev, 13, 11-22. https://doi.org/10.1158/1055-9965.EPI-083-3
  23. Koshiol J, Lindsay L, Pimenta JM, et al (2008). Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 168, 123-37. https://doi.org/10.1093/aje/kwn036
  24. Koshiol J, Hildesheim A, Gonzalez P, et al (2009). Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev, 18, 1631-7. https://doi.org/10.1158/1055-9965.EPI-08-0830
  25. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P) H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-9. https://doi.org/10.1093/carcin/21.10.1813
  26. Makni H, Franco EL, Kaiano J, et al (2000). P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer, 87, 528-33. https://doi.org/10.1002/1097-0215(20000815)87:4<528::AID-IJC11>3.0.CO;2-O
  27. Magnusson PK, Sparen P, Gyllensten UB (1999). Genetic link to cervical tumours. Nature, 400, 29-30. https://doi.org/10.1038/21801
  28. Meek DW (2009). Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer, 9, 714-23.
  29. Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of highrisk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci, 98, 1505-11. https://doi.org/10.1111/j.1349-7006.2007.00546.x
  30. Niwa Y, Hirose K, Nakanishi T, et al (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol, 96, 423-9. https://doi.org/10.1016/j.ygyno.2004.10.015
  31. Ojeda JM, Ampuero S, Rojas P, et al (2003). p53 codon 72 polymorphism and risk of cervical cancer. Biol Res, 36, 279-83.
  32. Oliveira S, Sousa H, Santos AM, et al (2008). The p53 R72P polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. J Med Virol, 80, 24-9.
  33. Pina-Sanchez P, Hernandez-Hernandez DM, Taja-Chayeb L, et al (2011). Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med Oncol, 28, 1507-13. https://doi.org/10.1007/s12032-010-9599-8
  34. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206. https://doi.org/10.1097/00008571-199508000-00003
  35. Rogler A, Rogenhofer M, Borchardt A, et al (2011). P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology, 78, 193-200. https://doi.org/10.1159/000326767
  36. Sauroja I, Smeds J, Vlaykova T, et al (2000). Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer, 28, 404-4. https://doi.org/10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P
  37. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9. https://doi.org/10.1097/00008571-199706000-00008
  38. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21. https://doi.org/10.1097/00008571-199902000-00015
  39. Zheng Y, Shen H, Sturgis EM, et al (2002). Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev, 11, 640-5.

Cited by

  1. SCYL1BP1 has Tumor-suppressive Functions in Human Lung Squamous Carcinoma Cells by Regulating Degradation of MDM2 vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7467
  2. Analysis of TP53 Polymorphisms in North Indian Sporadic Esophageal Cancer Patients vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8413
  3. polymorphisms with the severity of cervical neoplasia in a Brazilian population vol.19, pp.2, 2014, https://doi.org/10.3109/1354750X.2014.881419
  4. Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study vol.2, pp.4, 2014, https://doi.org/10.3892/br.2014.281
  5. Evidence for an Epistatic Effect between TP53 R72P and MDM2 T309G SNPs in HIV Infection: A Cross-Sectional Study in Women from South Brazil vol.9, pp.2, 2014, https://doi.org/10.1371/journal.pone.0089489
  6. Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma vol.13, pp.2, 2015, https://doi.org/10.3892/mmr.2015.4731
  7. Lack of Associations between TNF-α Polymorphisms and Cervical Cancer in Thai women vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.953
  8. CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions vol.56, pp.10, 2017, https://doi.org/10.1002/mc.22677
  9. Association of p16 (CDKN2A) polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population pp.01466615, 2017, https://doi.org/10.1002/jmv.24996